← Back to list
Announcement Details analyzed
ID
290
Seq No
106567184
Symbol
BALAXI
Company
BALAXI PHARMACEUTICALS LIMITED
Subject
Appointment
Category
Appointment
Description
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Appointment of Mr AMAN PUROHIT as Company Secretary & Compliance Officer of the company w.e.f. March 25, 2026.
Ann. Date
2026-03-25 13:14:32
Dissemination
25-Mar-2026 13:14:34
Attachment
📄 Download PDF BALAXI_25032026131415_Outcome_of_Board_Meeting.pdf
Created
2026-03-25T07:54:07.307Z
Updated
2026-03-25T07:56:10.283Z
AI Analysis claude-cli
High Impact Event
Company
Balaxi Pharmaceuticals Limited
Event
Appointment of Mr. Aman Purohit as Company Secretary and Compliance Officer w.e.f. 25th March 2026
Time
25th March 2026 (Board meeting: 11:45 a.m. – 12:50 p.m. IST)
Key Insight

This is a routine compliance appointment mandated under SEBI and Companies Act requirements. Mr. Purohit is an ACS (ICSI Membership A59345) with 6 years of post-qualification experience spanning M&A, corporate restructuring, fund-raising, and secretarial compliance across multiple industries.

Why it Matters

For a small-cap pharma company (₹98.38 Cr market cap), having a dedicated Company Secretary strengthens governance and regulatory compliance infrastructure. This suggests the company is professionalising its compliance function, which is a modest positive signal for minority investors monitoring governance quality.

Market Cap
₹98.38 Cr
Sector
Pharmaceuticals
Source
NSE Corporate Announcement
Link
NSE Announcements
Confidence Score
0/10
High impact event
  - Company Name: Balaxi Pharmaceuticals Limited
  - Event: Appointment of Mr. Aman Purohit as Company Secretary and Compliance Officer w.e.f. 25th March 2026
  - Time: 25th March 2026 (Board meeting: 11:45 a.m. – 12:50 p.m. IST)

Key Insight: This is a routine compliance appointment mandated under SEBI and Companies Act requirements. Mr. Purohit is an ACS (ICSI Membership A59345) with 6 years of post-qualification experience spanning M&A, corporate restructuring, fund-raising, and secretarial compliance across multiple industries.

Why it matters: For a small-cap pharma company (₹98.38 Cr market cap), having a dedicated Company Secretary strengthens governance and regulatory compliance infrastructure. This suggests the company is professionalising its compliance function, which is a modest positive signal for minority investors monitoring governance quality.

Market cap: ₹98.38 Cr
Sector: Pharmaceuticals
Confidence score: 0.05

Source: NSE Corporate Announcement
Link: https://www.nseindia.com/companies-listing/corporate-filings-announcements